Stelios Papadopoulos is Director at EXELIXIS, INC. (EXEL). They have made 28 open-market trades across 5 companies since 2007, most recently 2026-05-27.
CIK 0001202098
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
15 open-market purchases totalling $8.6M since 2007, against 13 sales. Across 9 scored buys the stock is down 14.2% at ninety days, and 18.8 points behind the S&P over the same stretch.
9 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 33% | 11% | 11% |
| Avg Move | -5.5% | -11.7% | -14.2% |
| Alpha | -4.8% | -12.8% | -18.8% |
| Scored | 9 | 9 | 9 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| EXEL | SELL | 2025-11-12 | 2025-11-13 | $43.55 | $4.4M | +2.9% | -1.3% | +2.4% |
| EXEL | SELL | 2025-05-15 | 2025-05-16 | $44.35 | $3.2M | -6.2% | -8.0% | -15.3% |
| EXEL | SELL | 2024-05-20 | 2024-05-22 | $21.00 | $240K | +3.4% | +5.6% | +25.9% |
| EXEL | SELL | 2022-02-22 | 2022-02-24 | $19.56 | $3.3M | +2.7% | +9.3% | -10.5% |
| EXEL | SELL | 2021-05-11 | 2021-05-13 | $24.97 | $911K | -10.7% | -9.1% | -30.3% |
| EXEL | SELL | 2020-05-08 | 2020-05-08 | $25.84 | $1.2M | -3.4% | -12.6% | -11.9% |
| RGLS | BUY | 2019-05-07 | 2019-05-08 | $1.08 | $400K | +4.1% | -27.0% | -53.7% |
| EXEL | SELL | 2019-02-21 | 2019-02-22 | $21.25 | $1.1M | +5.1% | +6.9% | -8.9% |
| RGLS | BUY | 2018-12-28 | 2019-01-02 | $1.09 | $109K | +0.0% | -17.5% | -5.3% |
| RGLS | BUY | 2018-12-26 | 2018-12-28 | $0.97 | $113K | +0.0% | -11.9% | -6.4% |
| RGLS | BUY | 2018-11-15 | 2018-11-19 | $1.37 | $1.1M | +8.1% | -36.5% | -32.2% |
| EXEL | SELL | 2018-05-07 | 2018-05-07 | $22.15 | $332K | -2.2% | -9.8% | -5.0% |
| EXEL | SELL | 2018-03-02 | 2018-03-02 | $24.05 | $361K | +4.3% | -9.9% | -13.1% |
| EXEL | SELL | 2017-09-22 | 2017-09-22 | $25.40 | $254K | +1.1% | +8.0% | +11.3% |
| EXEL | SELL | 2017-09-18 | 2017-09-20 | $27.68 | $11.1M | -14.0% | -3.7% | -5.5% |
| RGLS | BUY | 2017-07-25 | 2017-07-25 | $0.91 | $910K | -21.1% | -13.6% | +1.3% |
| RGLS | BUY | 2017-03-21 | 2017-03-23 | $1.22 | $609K | +18.5% | +3.7% | -29.7% |
| EXEL | SELL | 2017-03-20 | 2017-03-21 | $21.66 | $217K | +5.4% | +3.7% | +5.1% |
| BIIB | BUY | 2015-07-27 | 2015-07-27 | $304.88 | $3.0M | -11.0% | -1.9% | -1.9% |
| BIIB | SELL · 10b5-1 | 2013-06-11 | 2013-06-13 | $219.62 | $444K | -11.0% | -1.9% | -1.9% |
| BIIB | SELL · 10b5-1 | 2013-03-11 | 2013-03-12 | $172.26 | $8.0M | -11.0% | -1.9% | -1.9% |
| BGMD | BUY | 2013-01-30 | 2013-02-01 | $2.00 | $500K | N/A | N/A | N/A |
| BGMD | SELL | 2011-11-29 | 2011-12-01 | $4.01 | $4K | N/A | N/A | N/A |
| BGMD | BUY | 2011-02-09 | 2011-02-11 | $7.00 | $525K | N/A | N/A | N/A |
| EXEL | BUY | 2010-08-24 | 2010-08-25 | $3.05 | $548K | -24.2% | -0.2% | -0.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| ANDS |
| 814,206 |
| — |
| Total | $77.9M |
Shares reported on the most recent Form 4, priced at the 2026-05-29 close. 4 holdings could not be priced and are excluded from the total.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.